Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMO-3100 in moderate to severe plaque psoriasis
NCT01622348Phase 2Completed
- Sponsor
- Aceragen, Inc.
- Start
- May 2012
- Primary completion
- Nov 2012
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of IMO-3100 in plaque psoriasis, sponsored by Aceragen, Inc.. Started May 2012; status: completed.
02
Drugs
IMO-3100
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01622348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622348.